Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Profectus Biosciences, Inc.

http://www.profectusbiosciences.com/

Latest From Profectus Biosciences, Inc.

Aurobindo's US Respiratory Filing Could Rival Teva's Qvar

Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.

Sales & Earnings Strategy

Aurobindo Enters Fray For COVID-19 Vaccine

Building on assets acquired from Profectus BioSciences, Aurobindo Pharma has thrown its hat in the ring for a COVID-19 vaccine. Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, the company hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges.

Commercial Sales & Earnings

Ebola Vaccines: FDA Being ‘More Liberal’ On Accelerated Approval, Novavax Says

Advisory committee likes alternative trial designs, but says more data is needed on immune markers.

BioPharmaceutical Regulation

Ebola Vaccines: FDA Weighs Alternative Study Designs, Approval Pathways

As incidence of Ebola declines, advisory committee will consider alternatives to randomized controlled trials – an approach FDA had previously argued was inappropriate.

BioPharmaceutical Middle East and Africa
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register